论文部分内容阅读
目的：探讨抗胸腺细胞球蛋白（ＡＴＧ），在肾移植术后的应用价值与前景。方法：对６４例次使用ＡＴＧ的肾移植受者进行回顾性分析，比较其①对急性排异反应（ＡＲ）、急性加速性排异反应（ＡＡＲ）、超急性排异反应（ＨＡＲ）的预防与治疗情况；②对部分肾移植术后因各种原因暂不能使用常规免疫抑制剂者的替代与过渡治疗情况；③获得以上各种情况的治疗总剂量与总时限。结果：①ＡＴＧ对肾移植术后ＡＲ的逆转率为８２．３５％（１４／１７），对耐激素性ＡＲ的逆转率为７８．５７％（１１／１４），对ＡＡＲ的逆转率为１００％（１０／１０）；②ＡＴＧ制品适用于肾移植术后因各种原因暂不能服用常规免疫抑制剂者的替代与过渡治疗；③ＡＴＧ对ＨＡＲ不能起到预防与治疗的作用；④抗ＡＲ的ＡＴＧ治疗总剂量与时限以８００ｍｇ、５天为宜，抗ＡＡＲ的ＡＴＧ治疗总剂量与时限以７００ｍｇ、６天为宜，预防与替代治疗的总剂量与时限以７００ｍｇ、６天为宜。结论：ＡＴＧ适用于肾移植术后ＡＲ与ＡＡＲ的预防与治疗，特别对耐激素性排异反应以及暂时的替代与过渡治疗尤为合适，如果经济状况允许，应提倡使用。
Objective: To investigate the value and prospect of anti-thymocyte globulin (ATG) after renal transplantation. Methods: A total of 64 renal transplant recipients with ATG were retrospectively analyzed and compared for prevention of acute rejection (AR), acute acceleration rejection (AAR) and hyperacute rejection (HAR) And treatment; ② part of the renal transplant patients for various reasons temporarily can not use conventional immunosuppressive alternatives and transitional treatment; ③ access to the above conditions of the total dose and total duration of treatment. Results: ① The reversal rate of AR after renal transplantation was 82.35% (14/17), that of AR was 78.57% (11/14), and that of AAR was 100% (10/10); ② ATG products for renal transplant recipients for various reasons temporarily can not take conventional immunosuppressive agents and transitional treatment; ③ ATG HAR can not play a preventive and therapeutic role; ④ AT anti-AR treatment The total dose and time limit to 800mg, 5 days is appropriate, anti-AAR ATG total dose and time limit to 700mg, 6 days is appropriate, prevention and replacement therapy total dose and time to 700mg, 6 days is appropriate. CONCLUSIONS: ATG is suitable for the prevention and treatment of AR and AAR after renal transplantation, especially for steroid-resistant rejection and temporary replacement and transitional treatment. If economic status permits, ATG should be advocated.